SI2039682T1 - Dodatne soli inhibitorjev encima angiotenzin-konvertaze z no donorskimi kislinami, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo - Google Patents

Dodatne soli inhibitorjev encima angiotenzin-konvertaze z no donorskimi kislinami, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo

Info

Publication number
SI2039682T1
SI2039682T1 SI200830064T SI200830064T SI2039682T1 SI 2039682 T1 SI2039682 T1 SI 2039682T1 SI 200830064 T SI200830064 T SI 200830064T SI 200830064 T SI200830064 T SI 200830064T SI 2039682 T1 SI2039682 T1 SI 2039682T1
Authority
SI
Slovenia
Prior art keywords
conversing
angiotensin
inhibitors
enzyme
preparation
Prior art date
Application number
SI200830064T
Other languages
English (en)
Inventor
Nanteuil Guillaume De
Bernard Portevin
Philippe Gloanec
Jean-Gilles Parmentier
Alain Benoist
Tony Verbeuren
Alain Rupin
Christine Courchay
Serge Simonet
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39539691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2039682(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of SI2039682T1 publication Critical patent/SI2039682T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SI200830064T 2007-09-21 2008-09-19 Dodatne soli inhibitorjev encima angiotenzin-konvertaze z no donorskimi kislinami, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo SI2039682T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0706629A FR2921365B1 (fr) 2007-09-21 2007-09-21 Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP08290885A EP2039682B1 (fr) 2007-09-21 2008-09-19 Sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine avec des acides donneurs de NO, leur procédé de préparation et les compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
SI2039682T1 true SI2039682T1 (sl) 2010-10-29

Family

ID=39539691

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830064T SI2039682T1 (sl) 2007-09-21 2008-09-19 Dodatne soli inhibitorjev encima angiotenzin-konvertaze z no donorskimi kislinami, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo

Country Status (43)

Country Link
US (1) US7981920B2 (sl)
EP (2) EP2039682B1 (sl)
JP (1) JP4903187B2 (sl)
KR (1) KR101070056B1 (sl)
CN (1) CN101391973A (sl)
AP (1) AP2010005204A0 (sl)
AR (1) AR068488A1 (sl)
AT (1) ATE476416T1 (sl)
AU (1) AU2008217013B8 (sl)
BR (1) BRPI0804073A2 (sl)
CA (1) CA2639700C (sl)
CL (1) CL2008002725A1 (sl)
CR (1) CR11320A (sl)
CY (1) CY1110782T1 (sl)
DE (1) DE602008002027D1 (sl)
DK (1) DK2039682T3 (sl)
EA (1) EA015092B1 (sl)
EC (1) ECSP10010040A (sl)
ES (1) ES2349493T3 (sl)
FR (1) FR2921365B1 (sl)
GE (1) GEP20125479B (sl)
HN (1) HN2010000533A (sl)
HR (1) HRP20100545T1 (sl)
JO (1) JO2664B1 (sl)
MA (1) MA30320B1 (sl)
MX (1) MX2008011954A (sl)
MY (1) MY144927A (sl)
NI (1) NI201000038A (sl)
NZ (1) NZ572988A (sl)
PA (1) PA8796701A1 (sl)
PE (1) PE20091190A1 (sl)
PL (1) PL2039682T3 (sl)
PT (1) PT2039682E (sl)
RS (1) RS51433B (sl)
SA (1) SA08290599B1 (sl)
SG (1) SG151200A1 (sl)
SI (1) SI2039682T1 (sl)
SV (1) SV2010003511A (sl)
TN (1) TN2010000111A1 (sl)
TW (1) TWI370118B (sl)
UY (1) UY31339A1 (sl)
WO (1) WO2009074733A2 (sl)
ZA (1) ZA200808062B (sl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
US10314816B2 (en) 2012-06-08 2019-06-11 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
CN103848795B (zh) * 2014-03-07 2016-08-17 山东大学 一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4218582A1 (de) * 1992-06-05 1993-12-09 Cassella Ag Pyridyl-1,2,5-oxadiazol-carbonamid-2-oxide
IT1295694B1 (it) * 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
CA2340206A1 (en) * 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti-pressor agents for vascular remodeling in genital dysfunction
DE10033580A1 (de) 2000-04-10 2001-10-11 Bayer Ag Verfahren zur Herstellung von Ditaurin und seinen Salzen
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
EP1578413A2 (en) * 2002-11-29 2005-09-28 Yissum Research Development Company of The Hebrew University of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
WO2005018561A2 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2006078995A1 (en) * 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
EP1877374A1 (en) * 2005-03-18 2008-01-16 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin converting enzyme inhibitors, compositions and methods of use
RU2271202C1 (ru) * 2005-05-04 2006-03-10 Михаил Владимирович Покровский Способ коррекции эндотелиальной дисфункции
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
EP1954685A4 (en) * 2005-11-16 2009-11-11 Nitromed Inc FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
ATE485261T1 (de) * 2005-11-23 2010-11-15 Nicox Sa Salicylsäurederivate

Also Published As

Publication number Publication date
CY1110782T1 (el) 2015-06-10
CA2639700A1 (fr) 2009-03-21
EP2039682A1 (fr) 2009-03-25
UY31339A1 (es) 2008-10-31
TW200920352A (en) 2009-05-16
EA200801863A1 (ru) 2009-04-28
JO2664B1 (en) 2012-06-17
EA015092B1 (ru) 2011-06-30
AU2008217013B2 (en) 2012-08-16
JP2009137935A (ja) 2009-06-25
TN2010000111A1 (fr) 2011-09-26
ATE476416T1 (de) 2010-08-15
EP2039682B1 (fr) 2010-08-04
GEP20125479B (en) 2012-04-25
KR20090031298A (ko) 2009-03-25
PT2039682E (pt) 2010-09-27
US7981920B2 (en) 2011-07-19
HRP20100545T1 (hr) 2010-11-30
AU2008217013A8 (en) 2012-10-04
AU2008217013A1 (en) 2009-04-09
KR101070056B1 (ko) 2011-10-04
HN2010000533A (es) 2013-07-08
FR2921365A1 (fr) 2009-03-27
NI201000038A (es) 2010-07-15
MY144927A (en) 2011-11-30
BRPI0804073A2 (pt) 2009-06-16
FR2921365B1 (fr) 2012-10-12
AR068488A1 (es) 2009-11-18
CN101391973A (zh) 2009-03-25
DE602008002027D1 (de) 2010-09-16
ES2349493T3 (es) 2011-01-04
US20090082393A1 (en) 2009-03-26
AP2010005204A0 (en) 2010-04-30
PA8796701A1 (es) 2009-09-17
PE20091190A1 (es) 2009-08-09
ECSP10010040A (es) 2010-04-30
ZA200808062B (en) 2009-11-25
SA08290599B1 (ar) 2011-05-04
DK2039682T3 (da) 2010-11-08
MX2008011954A (es) 2009-03-20
AU2008217013B8 (en) 2012-10-04
PL2039682T3 (pl) 2010-10-29
CR11320A (es) 2010-06-29
CA2639700C (fr) 2012-08-28
WO2009074733A2 (fr) 2009-06-18
EP2236495A1 (fr) 2010-10-06
JP4903187B2 (ja) 2012-03-28
SV2010003511A (es) 2010-07-29
SG151200A1 (en) 2009-04-30
WO2009074733A3 (fr) 2009-08-20
NZ572988A (en) 2010-07-30
MA30320B1 (fr) 2009-04-01
RS51433B (en) 2011-04-30
CL2008002725A1 (es) 2009-06-12
TWI370118B (en) 2012-08-11

Similar Documents

Publication Publication Date Title
AP3346A (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
IL211683A0 (en) 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
EP1996213A4 (en) METHOD AND COMPOSITIONS FOR POTENTIATING MEDICINES USING AMINO ACID-BASED THERAPEUTIC FOODS
DK2282994T3 (da) 3-aminocarbazolforbindelse, farmaceutisk sammensætning indeholdende forbindelsen samt fremstillingsmetode derfor
PT1902706T (pt) Composições farmacêuticas estáveis de tetraciclinas em solução, seu método de obtenção e suas utilizações
IL214236A0 (en) Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1
ZA201104523B (en) Preparation method of dihydroindene amide compounds,their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor
IL202203B (en) An artificial bile acid preparation and a method for preparing the acid
HK1164292A1 (en) Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
EP2358691B8 (en) Process for the preparation of piperazine compounds and hydrochloride salts thereof
IL211018A (en) Inhibitors, processes for making them, medicinal preparations containing them and their use
IL210708A0 (en) Imidazo [1,2-a]pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as met inhibitors
EP2038282A4 (en) SALTS OF PYRROLOPYRIMIDINONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
PL1989182T3 (pl) Postać krystaliczna soli peryndoprylu z argininą, sposób jej wytwarzania i kompozycje farmaceutyczne ją zawierające
IL195473A (en) Diphosphate Acetic Acid Derivatives as Glycine Transporter Inhibitors-1, Method for Preparing, Using Pharmaceutical Preparations
EP2212325A4 (en) 2-ARYLMETHYLAZETIDINCARBAPENEM-3-CARBOXYLENE DERTERIVATE OR SALT, METHOD FOR THE PRODUCTION THEREOF AND THEREOF COMPRISING PHARMACEUTICAL COMPOSITION
EP2361907A4 (en) THE FIVE CRYSTALLINE FORMS OF NICOUSAMIDE, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
PL2039682T3 (pl) Sole addycyjne inhibitorów enzymów konwersji angiotensyny z kwasami będącymi donorami NO, sposób ich wytwarzania i kompozycje farmaceutyczne, które je zawierają
HK1209022A1 (en) Amino acid derivatives used as pharmaceutical substances
IL195958A0 (en) Phenylacetic acid derivatives as cox-2 inhibitors
HK1129687A1 (en) A process for the preparation of poly-alfa-glutamic acid and derivatives thereof
PL2213653T3 (pl) Sposób stereoselektywnego wytwarzania pochodnych aminokwasów
PL382311A1 (pl) Kompozycja farmaceutyczna o polepszonej stabilności zawierająca inhibitor acetylocholinoesterazy lub farmaceutycznie dopuszczalną jego sól oraz sposób jej wytwarzania
IL210842A (en) A single solid product containing protein, protease inhibitor and salt of nac or nad and use of this preparation for oral administration of the protein